Metronomics Global Health Initiative

Home page > People > Supporters > Giuseppe CURIGLIANO


Giuseppe Curigliano, MD, PhD, is Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where besides his clinical work.

He is a clinician and researcher specializing in breast cancer.

Dr. Curigliano earned his MD at the Universita’ Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection.

He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 3 years in the phase I unit, contributing to successful development of several targeted agents and cytotoxics. Since 2001 he is assistant professor of Clinical Pharmacology at University of Milan. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of Division of Clinical Oncology coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). His clinical experience is based on a daily clinical management of patients with solid tumors,within a comprehensive cancer center accepting every year at least 85.000 first diagnosis atients. He practice in the in patient, out patient and day hospital setting. He served for 3 ears on emergency an palliative care section of the Division.

He is an active member of the merican Society of Clinical Oncology (ASCO), the European Society of Medical Oncology ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member f/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He serveson the Clinical Research Committee of the AIOM. He serves as faculty member in the uropean School of Oncology (ESO). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference 2013 and served ad Chair of the metastatic breast cancer track for ESMO 2014 meeting in Madrid.

Dr. Curigliano’s research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting).

Dr Curigliano’s research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development in breast cancer at European Institute of Oncology. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 160 peer reviewed article, most of them as first author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute, the European Journal of Cancer and many other “breast oriented journals”. He is member of the Editorial Board of Journal of Clinical Oncology and Annals of Oncology. He serves in the press committee of the European Society of Medical Oncology as Spokesperson coordinator for breast cancer.